Outpatient minimally invasive transforaminal lumbar interbody fusion performed at a single ambulatory surgery center: the Semmes Murphey Clinic experience

Neurosurg Focus 60(4):E5, 2026

This study reports outcomes from 179 patients undergoing single-level minimally invasive transforaminal lumbar interbody fusion (miTLIF) at a single ambulatory surgery center (ASC) between 2012–2024. It presents demographics, surgical details, complications, and validated patient-reported outcomes with 2-year follow-up showing sustained pain reduction, functional improvement, and high satisfaction.

The authors detail selection criteria, perioperative technique using tubular retractors and percutaneous pedicle screws, low complication and 90-day readmission/reoperation rates, and discuss economic and policy implications for ASC-based lumbar fusion care.

Objective Report 2-year outcomes for outpatient minimally invasive TLIF (miTLIF) performed at a single ambulatory surgery center (ASC).

Cohort 485 single-level miTLIFs were performed at the ASC (2012–2024); 179 registry-enrolled patients were analyzed (mean age 54; BMI mean 31).

Selection ASC eligibility exclusions included BMI > 50, weight > 350 lb, cardiac disease not cleared “low risk,” ASA class IIIb or above, family history of malignant hyperthermia, or inability to ambulate; Medicare primary insurance was also excluded for reimbursement reasons.

Disposition 98.3% were discharged within a few hours; 1.1% observed < 23 hours for pain control; 0.56% required hospital transfer for new-onset atrial fibrillation (treated and discharged within 23 hours).

Patient-reported outcomes Mean scores improved from baseline to 3 months and remained improved through 2 years (e.g., back pain NRS 6.98→2.40 at 3 months and 2.86 at 2 years; ODI 44.14→19.37 at 3 months and 13.87 at 2 years; EQ-5D 0.56→0.81 at 3 months and 0.82 at 2 years).

Complications Durotomy occurred in 1.7% (treated with fibrin glue, discharged within hours); superficial surgical site infection 0.56% (oral antibiotics only); postoperative hematoma 0.56%; urinary tract infection 0.56%.

Readmissions/reoperations (90-day) 2.2% readmissions and 1.1% reoperations within 90 days (including hardware failure and delayed hematoma).

Conclusion For carefully selected patients, ASC-based miTLIF showed significant, durable PROM improvement with acceptably low complications, readmissions, and reoperations.